K. Prestin

Modulation of expression of the nuclear receptor NR0B2 (small heterodimer partner 1) and its impact on proliferation of renal carcinoma cells

H. E. Meyer zu Schwabedissen, U. Zimmermann, J. Hussner, 2016, OncoTargets and therapy.

Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects

M. Liechti, H. M. Z. Schwabedissen, P. Vizeli, 2017, European Neuropsychopharmacology.

Transcriptional regulation of urate transportosome member SLC2A9 by nuclear receptor HNF4α.

H. Kroemer, H. E. Meyer zu Schwabedissen, C. Rimmbach, 2014, American journal of physiology. Renal physiology.

PDZ domain containing protein 1 (PDZK1), a modulator of membrane proteins, is regulated by the nuclear receptor THRβ

H. M. Z. Schwabedissen, U. Zimmermann, J. Hussner, 2017, Molecular and Cellular Endocrinology.

Regulation of PDZ domain-containing 1 (PDZK1) expression by hepatocyte nuclear factor-1α (HNF1α) in human kidney.

H. E. Meyer zu Schwabedissen, I. Seibert, U. Zimmermann, 2017, American journal of physiology. Renal physiology.

Expression of OATP2B1 as determinant of drug effects in the microcompartment of the coronary artery.

H. E. Meyer zu Schwabedissen, J. Hussner, D. Gliesche, 2015, Vascular pharmacology.

CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals

M. Liechti, H. E. Meyer zu Schwabedissen, P. Vizeli, 2016, Pharmacogenetics and genomics.

Functional assessment of genetic variants located in the promoter of SHP1 (NR0B2).

H. Völzke, H. E. Meyer zu Schwabedissen, J. Hussner, 2017, Pharmacogenetics and genomics.

Pharmacogenetics of MDMA 1 Supplementary Material CYP 2 D 6 function moderates the pharmacokinetics and pharmacodynamics of MDMA in a controlled study in healthy subjects

M. Liechti, P. Vizeli, Y. Schmid, 2016 .